PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of gutGutVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Gut. 2001 September; 49(3): 395–401.
PMCID: PMC1728418

Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial

Abstract

INTRODUCTION—Erythromycin, a motilin agonist, is a potent prokinetic. ABT-229 is a specific motilin agonist that dose dependently accelerates gastric emptying. Dyspepsia and gastroparesis are common problems in type 1 diabetes mellitus. We aimed to evaluate the efficacy of ABT-229 in symptomatic diabetic patients with and without delayed gastric emptying.
METHODS—Patients with type 1 diabetes and postprandial symptoms were randomised (n=270). Based on a validated C13 octanoic acid breath test, patients were assigned to either the delayed or normal gastric emptying strata. Patients received one of four doses of ABT-229 (1.25, 2.5, 5, or 10 mg twice daily before breakfast and dinner) or placebo for four weeks following a two week baseline. A self report questionnaire measured symptoms on visual analogue scales; the primary outcome was assessment of change in the total upper abdominal symptom severity score (range 0-800 mm) from baseline to the final visit.
RESULTS—The treatment arms were similar regarding baseline characteristics. There was symptom improvement on placebo and a similar level of improvement on active therapy for the upper abdominal discomfort severity score (mean change from baseline −169, −101, −155, −143, and −138 mm for placebo, and 1.25, 2.5, 5, and 10 mg ABT-229, respectively, at four weeks by intent to treat). The results were not significantly different in those with and without delayed gastric emptying. The severity of bloating, postprandial nausea, epigastric discomfort, heartburn, and acid regurgitation worsened dose dependently in a greater number of patients receiving ABT-229 than placebo. Overall, 63% of patients on placebo reported a good or excellent global response, and this was not different from the active treatment arms.
CONCLUSIONS—The motilin agonist ABT-229 was not efficacious in the relief of postprandial symptoms in diabetes mellitus in the presence or absence of delayed gastric emptying.


Keywords: prokinetic; motilin; dyspepsia; gastric motility; type 1 diabetes; controlled trial; postprandial

Figure 1
Patient flow chart.
Figure 2
Distribution of gastric emptying half times (t1/2) in the study population.
Figure 3
Mean upper abdominal discomfort score on combined visual analogue scales (mm) at baseline (B) and at the four week (final (F)) visit in each treatment arm.
Figure 4
Change from baseline for the sum of daily severity scores for fullness, bloating, epigastric discomfort, and postprandial nausea from the patient diary in the placebo and ABT-229 10 mg groups.

Articles from Gut are provided here courtesy of BMJ Group